ERBB2 and breast carcinoma: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for 26%–50% of all breast cancers in the Indian population and is associated with an inferior survival outcome mostly attributable to lack of access to an appropriate anti-HER2 therapy [1].